Literature DB >> 20012239

Comparing exponentially weighted moving average and run rules in process control of semiquantitative immunogenicity immunoassays.

Troy E Barger1, Lei Zhou, Michael Hale, Michael Moxness, Steven J Swanson, Narendra Chirmule.   

Abstract

The immunogenicity immunoassay validation process ensures development of a robust, reproducible method. However, no matter how well developed, validated, and maintained a method is, in the course of running a large number of samples over time, it is not uncommon to see bad reagents, poorly calibrated equipment, personnel errors, or other unknown and unpredictable factors that have an impact in the performance of the method and quality of the sample results. The immunogenicity immunoassay thus needs to be closely monitored with an internal statistical quality control process overtime to ensure a consistent and reliable output. The statistical process control has been widely applied to monitor manufacturing processes and in clinical laboratories. Its application to immunogenicity immunoassays is relatively novel. Limited guidance is available to implement the process to monitor semiquantitative immunogenicity immunoassay performance. Here, we have performed a suitability evaluation for process control charts with actual laboratory data from three immunogenicity immunoassay methods each utilizing a different technology platform. Additionally, a panel of prepared samples designed to assess long-term method performance were periodically evaluated for over a year. Finally, we make recommendations for an internal quality control process based on the results of these evaluations.

Mesh:

Year:  2009        PMID: 20012239      PMCID: PMC2811647          DOI: 10.1208/s12248-009-9166-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  9 in total

1.  Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  1992-02-28

2.  Internal quality control system for non-stationary, non-ergodic analytical processes based upon exponentially weighted estimation of process means and process standard deviation.

Authors:  Rob T P Jansen; Mark Laeven; Wim Kardol
Journal:  Clin Chem Lab Med       Date:  2002-06       Impact factor: 3.694

3.  Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies.

Authors:  Michael Moxness; Suzanna Tatarewicz; Dohan Weeraratne; Nancy Murakami; Danika Wullner; Dan Mytych; Vibha Jawa; Eugen Koren; Steven J Swanson
Journal:  Clin Chem       Date:  2005-10       Impact factor: 8.327

4.  The exponentially weighted moving average (EWMA) rule compared with traditionally used quality control rules.

Authors:  Kristian Linnet
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

5.  The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum.

Authors:  Daniel T Mytych; Stephon La; Troy Barger; John Ferbas; Steven J Swanson
Journal:  J Pharm Biomed Anal       Date:  2008-11-27       Impact factor: 3.935

6.  The use of control charts in the clinical laboratory.

Authors:  S LEVEY; E R JENNINGS
Journal:  Am J Clin Pathol       Date:  1950-11       Impact factor: 2.493

7.  The EWMA control chart: properties and comparison with other quality-control procedures by computer simulation.

Authors:  A S Neubauer
Journal:  Clin Chem       Date:  1997-04       Impact factor: 8.327

8.  A multi-rule Shewhart chart for quality control in clinical chemistry.

Authors:  J O Westgard; P L Barry; M R Hunt; T Groth
Journal:  Clin Chem       Date:  1981-03       Impact factor: 8.327

9.  Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

Authors:  James A Lofgren; Sripriya Dhandapani; Jason J Pennucci; Christina M Abbott; Daniel T Mytych; Arunan Kaliyaperumal; Steven J Swanson; Michael C Mullenix
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

  9 in total
  1 in total

1.  Immunogenicity of panitumumab in combination chemotherapy clinical trials.

Authors:  Dohan Weeraratne; Alin Chen; Jason J Pennucci; Chi-Yuan Wu; Kathy Zhang; Jacqueline Wright; Juan José Pérez-Ruixo; Bing-Bing Yang; Arunan Kaliyaperumal; Shalini Gupta; Steven J Swanson; Narendra Chirmule; Marta Starcevic
Journal:  BMC Clin Pharmacol       Date:  2011-11-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.